Townsquare Capital LLC Cuts Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Townsquare Capital LLC lessened its stake in AtriCure, Inc. (NASDAQ:ATRC) by 4.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 16,138 shares of the medical device company’s stock after selling 789 shares during the quarter. Townsquare Capital LLC’s holdings in AtriCure were worth $493,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in ATRC. Blue Trust Inc. boosted its position in shares of AtriCure by 1.8% during the 4th quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company’s stock worth $414,000 after acquiring an additional 265 shares in the last quarter. Invesco Ltd. lifted its stake in AtriCure by 0.8% during the fourth quarter. Invesco Ltd. now owns 43,647 shares of the medical device company’s stock worth $1,334,000 after purchasing an additional 334 shares during the last quarter. Perkins Capital Management Inc. boosted its holdings in AtriCure by 1.3% in the fourth quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company’s stock valued at $927,000 after purchasing an additional 400 shares in the last quarter. Truist Financial Corp boosted its holdings in AtriCure by 2.6% in the fourth quarter. Truist Financial Corp now owns 15,717 shares of the medical device company’s stock valued at $480,000 after purchasing an additional 403 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in AtriCure by 0.9% during the third quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company’s stock worth $1,569,000 after purchasing an additional 484 shares in the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other AtriCure news, Director Karen Prange sold 6,100 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now owns 17,828 shares of the company’s stock, valued at $679,603.36. This represents a 25.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 3.20% of the company’s stock.

AtriCure Stock Performance

NASDAQ:ATRC opened at $32.01 on Monday. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -33.69 and a beta of 1.65. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $43.11. The firm’s fifty day moving average price is $35.10 and its 200 day moving average price is $34.46.

Wall Street Analyst Weigh In

A number of research firms recently commented on ATRC. Needham & Company LLC reaffirmed a “buy” rating and issued a $51.00 target price on shares of AtriCure in a research report on Thursday, March 27th. Piper Sandler raised their price objective on AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. reduced their target price on AtriCure from $51.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, March 27th. Oppenheimer upped their target price on AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th. Finally, Canaccord Genuity Group reduced their price objective on AtriCure from $66.00 to $52.00 and set a “buy” rating for the company in a research note on Friday, March 28th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.44.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.